- Home
- NRSN vs ONCO Comparison
NRSN vs ONCO Comparison
Compare NRSN & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- ONCO
- Stock Information
- Founded
- NRSN 2017
- ONCO 2018
- Country
- NRSN Israel
- ONCO United States
- Employees
- NRSN N/A
- ONCO N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- NRSN Health Care
- ONCO Health Care
- Exchange
- NRSN Nasdaq
- ONCO Nasdaq
- Market Cap
- NRSN 26.3M
- ONCO 24.1M
- IPO Year
- NRSN 2021
- ONCO 2022
- Fundamental
- Price
- NRSN $1.31
- ONCO $1.67
- Analyst Decision
- NRSN
- ONCO
- Analyst Count
- NRSN 0
- ONCO 0
- Target Price
- NRSN N/A
- ONCO N/A
- AVG Volume (30 Days)
- NRSN 181.1K
- ONCO 65.2K
- Earning Date
- NRSN 11-26-2024
- ONCO 11-26-2024
- Dividend Yield
- NRSN N/A
- ONCO N/A
- EPS Growth
- NRSN N/A
- ONCO N/A
- EPS
- NRSN N/A
- ONCO N/A
- Revenue
- NRSN N/A
- ONCO $1,463,746.00
- Revenue This Year
- NRSN N/A
- ONCO N/A
- Revenue Next Year
- NRSN N/A
- ONCO N/A
- P/E Ratio
- NRSN N/A
- ONCO N/A
- Revenue Growth
- NRSN N/A
- ONCO N/A
- 52 Week Low
- NRSN $0.47
- ONCO $1.61
- 52 Week High
- NRSN $2.33
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- NRSN 61.44
- ONCO 25.33
- Support Level
- NRSN $1.23
- ONCO $1.70
- Resistance Level
- NRSN $1.34
- ONCO $2.53
- Average True Range (ATR)
- NRSN 0.10
- ONCO 0.27
- MACD
- NRSN 0.01
- ONCO -0.13
- Stochastic Oscillator
- NRSN 75.00
- ONCO 4.93
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.